Yanming He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanming He has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Hongjie Yang
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
10 shared publicationsJiawen You
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
8 shared publicationsXiaoli He
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
8 shared publicationsXiaoxiao Qu
Department of Endocrinology, Center of Experimental Animals, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
8 shared publicationsXinyi Fu
Department of Endocrinology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
6 shared publicationsJiayuan Cai
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1924512
Single-cell virtual knockout network perturbation prioritizes candidate regulators of beta-cell functional failure in type 2 diabetes
Background: Progressive pancreatic beta-cell dysfunction is a central feature of type 2 diabetes (T2D), but disease-associated transcriptional changes alone cannot distinguish likely regulatory drivers from secondary stress markers. Single-cell transcriptomics resolves beta-cell heterogeneity across disease states, while virtual-knockout network analysis estimates transcriptional effects after perturbing selected genes. We combined human islet single-cell RNA sequencing, beta-cell functional-state modeling, candidate scoring, scTenifoldKnk virtual knockout, and external validation to prioritize regulators associated with T2D-related beta-cell functional failure. Methods: We analyzed the official processed GSE221156 beta-cell matrix at two levels. Cell-level analyses described beta-cell states, whereas donor-level pseudobulk models covered 48 donors and adjusted for sex, age, BMI, sequencing chemistry, and ethnicity. We then connected a prior-free genome-wide screen to an independent scTenifoldKnk network-evidence analysis. The fixed 14-gene panel was tested against random panels matched for expression, detection, and network in- and out-strength. For the scale experiment, each network contained 200, 500, or 1,000 cells, and each setting used 3, 5, or 10 independently inferred networks across three seeds. Expression evidence came from GSE153855, GSE81608, GSE101207, and GSE50244; orthogonal perturbation evidence came from GSE52258, GSE230728, primary-human-pseudoislet PCSK1 CRISPR data, and quantitative PCSK2 and SLC2A2 studies. A 2,000-cell point was additionally evaluated at the primary 10-network setting. Results: GSE221156 captured substantial beta-cell heterogeneity and a redistribution of cell states. Of 26,164 expressed genes, 17,989 passed pseudobulk filtering, and 674 (3.75%) differed significantly between T2D and ND after adjustment. Larger GRNs ranked ATF4, DKK3, SLC30A8, PCSK1, and SLC2A2 highest within the prespecified 14-gene panel. The fixed 14-gene panel also exceeded 200,000 expression-, detection-, and network-strength-matched random panels (observed mean 0.619; null mean 0.578; empirical P = 0.0111). Evidence varied across individual candidates, and none survived correction across the 14 genes. Scale mattered: median cross-seed whole-profile Spearman correlation rose from 0.265 with 200 cells and 3 networks to 0.884 with 1,000 cells and 10 networks and reached 0.913 with 2,000 cells and 10 networks. Across three external beta-cell cohorts, DKK3, PCSK2, SLC2A2, and ASCL2 retained concordant directions. Conclusions: By anchoring network perturbation to donor-level disease signals, our framework maps regulatory vulnerability in T2D beta cells. The matched-null analysis identifies collective network information in the fixed 14-gene panel beyond expression and connectivity. Within this collectively enriched panel, the expanded GRNs place ATF4, DKK3, SLC30A8, PCSK1, and SLC2A2 at the leading ranks, defining focused candidates for experimental testing.
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1924512
Open AccessSingle-cell virtual knockout network perturbation prioritizes candidate regulators of beta-cell functional failure in type 2 diabetes
Background: Progressive pancreatic beta-cell dysfunction is a central feature of type 2 diabetes (T2D), but disease-associated transcriptional changes alone cannot distinguish likely regulatory drivers from secondary stress markers. Single-cell transcriptomics resolves beta-cell heterogeneity across disease states, while virtual-knockout network analysis estimates transcriptional effects after perturbing selected genes. We combined human islet single-cell RNA sequencing, beta-cell functional-state modeling, candidate scoring, scTenifoldKnk virtual knockout, and external validation to prioritize regulators associated with T2D-related beta-cell functional failure. Methods: We analyzed the official processed GSE221156 beta-cell matrix at two levels. Cell-level analyses described beta-cell states, whereas donor-level pseudobulk models covered 48 donors and adjusted for sex, age, BMI, sequencing chemistry, and ethnicity. We then connected a prior-free genome-wide screen to an independent scTenifoldKnk network-evidence analysis. The fixed 14-gene panel was tested against random panels matched for expression, detection, and network in- and out-strength. For the scale experiment, each network contained 200, 500, or 1,000 cells, and each setting used 3, 5, or 10 independently inferred networks across three seeds. Expression evidence came from GSE153855, GSE81608, GSE101207, and GSE50244; orthogonal perturbation evidence came from GSE52258, GSE230728, primary-human-pseudoislet PCSK1 CRISPR data, and quantitative PCSK2 and SLC2A2 studies. A 2,000-cell point was additionally evaluated at the primary 10-network setting. Results: GSE221156 captured substantial beta-cell heterogeneity and a redistribution of cell states. Of 26,164 expressed genes, 17,989 passed pseudobulk filtering, and 674 (3.75%) differed significantly between T2D and ND after adjustment. Larger GRNs ranked ATF4, DKK3, SLC30A8, PCSK1, and SLC2A2 highest within the prespecified 14-gene panel. The fixed 14-gene panel also exceeded 200,000 expression-, detection-, and network-strength-matched random panels (observed mean 0.619; null mean 0.578; empirical P = 0.0111). Evidence varied across individual candidates, and none survived correction across the 14 genes. Scale mattered: median cross-seed whole-profile Spearman correlation rose from 0.265 with 200 cells and 3 networks to 0.884 with 1,000 cells and 10 networks and reached 0.913 with 2,000 cells and 10 networks. Across three external beta-cell cohorts, DKK3, PCSK2, SLC2A2, and ASCL2 retained concordant directions. Conclusions: By anchoring network perturbation to donor-level disease signals, our framework maps regulatory vulnerability in T2D beta cells. The matched-null analysis identifies collective network information in the fixed 14-gene panel beyond expression and connectivity. Within this collectively enriched panel, the expanded GRNs place ATF4, DKK3, SLC30A8, PCSK1, and SLC2A2 at the leading ranks, defining focused candidates for experimental testing.
- 13 June 2026
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (7) , 1-18
Association between immune-inflammatory biomarkers (NLR, PLR, SII, SIRI) and obesity in adults: a systematic review and meta-analysis
Background Obesity is regarded as a chronic, low-grade systemic inflammatory condition. However, whether immune–inflammatory indices derived from routine peripheral blood tests—including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—can accurately reflect obesity-associated inflammation remains controversial, as existing studies have reported inconsistent findings. Comparing these indices between people with obesity and people without obesity, and further evaluating sources of heterogeneity and their potential clinical implications, is of considerable significance for clarifying their role in obesity research and clinical application. Methods Relevant studies published up to September 30, 2025, were systematically searched in PubMed, EMBASE, the Cochrane Library, and Web of Science databases. A meta-analysis was conducted using standardized mean differences (SMDs) to evaluate overall effects, with additional subgroup and sensitivity analyses performed (PROSPERO registration number: CRD420251247523). Results A total of 30 studies were included, comprising 94,408 people with obesity and 129,927 people without obesity as controls. The meta-analysis demonstrated that NLR (SMD = 0.46, 95% CI: 0.10–0.82, p < 0.001), SII (SMD = 2.45, 95% CI: 0.89– 4.01, p < 0.001), and SIRI (SMD = 0.84, 95% CI: 0.47–1.22, p < 0.001) were significantly higher in the group of people with obesity compared with controls, whereas PLR showed no statistically significant difference (SMD = 0.00, 95% CI: −0.08–0.09, p > 0.05). Subgroup analyses indicated that these associations were more prominent in studies defining obesity by BMI, among individuals with chronic comorbidities, and within Asian and American populations. Conclusion NLR, SII, and SIRI may serve as potential low-cost biomarkers reflecting systemic inflammation associated with obesity, while PLR appears to have limited applicability. Future high-quality prospective studies are needed to validate their clinical utility in obesity risk stratification, prediction of complications, and monitoring of therapeutic responses, as well as to explore the potential value of combining these indices with traditional inflammatory and metabolic biomarkers.
- 13 June 2026
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (7) , 1-18
Association between immune-inflammatory biomarkers (NLR, PLR, SII, SIRI) and obesity in adults: a systematic review and meta-analysis
Background Obesity is regarded as a chronic, low-grade systemic inflammatory condition. However, whether immune–inflammatory indices derived from routine peripheral blood tests—including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—can accurately reflect obesity-associated inflammation remains controversial, as existing studies have reported inconsistent findings. Comparing these indices between people with obesity and people without obesity, and further evaluating sources of heterogeneity and their potential clinical implications, is of considerable significance for clarifying their role in obesity research and clinical application. Methods Relevant studies published up to September 30, 2025, were systematically searched in PubMed, EMBASE, the Cochrane Library, and Web of Science databases. A meta-analysis was conducted using standardized mean differences (SMDs) to evaluate overall effects, with additional subgroup and sensitivity analyses performed (PROSPERO registration number: CRD420251247523). Results A total of 30 studies were included, comprising 94,408 people with obesity and 129,927 people without obesity as controls. The meta-analysis demonstrated that NLR (SMD = 0.46, 95% CI: 0.10–0.82, p < 0.001), SII (SMD = 2.45, 95% CI: 0.89– 4.01, p < 0.001), and SIRI (SMD = 0.84, 95% CI: 0.47–1.22, p < 0.001) were significantly higher in the group of people with obesity compared with controls, whereas PLR showed no statistically significant difference (SMD = 0.00, 95% CI: −0.08–0.09, p > 0.05). Subgroup analyses indicated that these associations were more prominent in studies defining obesity by BMI, among individuals with chronic comorbidities, and within Asian and American populations. Conclusion NLR, SII, and SIRI may serve as potential low-cost biomarkers reflecting systemic inflammation associated with obesity, while PLR appears to have limited applicability. Future high-quality prospective studies are needed to validate their clinical utility in obesity risk stratification, prediction of complications, and monitoring of therapeutic responses, as well as to explore the potential value of combining these indices with traditional inflammatory and metabolic biomarkers.
- Open Access
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1772033
Daixie recipe ameliorates diet-induced MASH in mice via activating PI3K/AKT and Keap1/Nrf2 signaling
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a highly prevalent liver disease that can progress to cirrhosis and hepatocellular carcinoma. Despite its growing clinical burden, effective therapies remain limited. Daixie recipe (DXR), derived from Danggui Shaoyao San in Jingui Yaolue , has shown notable clinical efficacy in treating MASH, yet its underlying pharmacological mechanisms remain to be clarified. Purpose: To clarify the pharmacological effects of DXR and to elucidate the underlying mechanisms of DXR for treating MASH. Methods: UHPLC-Q-Orbitrap HRMS was used to identify the phytochemcials in DXR. The key targets and ingredients for combating MASH were explored by using a suite of in vitro and in vivo experiments, as well as molecular dynamics simulations and bioinformatics analysis. The MASH model was established in C57BL/6 male mice by feeding either a high-fat, high-fructose, high-cholesterol diet or a methionine- and choline-deficient (MCD) diet. ELISA and Western Blotting were used to measure liver tissue pathology, serum biochemistry, lipid synthesis enzymes, oxidative stress markers, pro-inflammatory mediators, apoptosis-related factors, and p -AKT1, Nrf2, and HO-1 expression. The effects of DXR on the PI3K/AKT pathway and Keap1/Nrf2 signaling were analyzed in free fatty acid-induced AML12 cells and HEK293-Nrf2-Luc cells. Results: DXR shows significant therapeutic efficacy in ameliorating hepatic steatosis and inflammation, as evidenced by the marked reduction in the levels of serum biomarkers (such as ALT, AST, TG, TC, and LDL-c). Phytochemcial analysis coupling with network pharmacology analyses identify key targets of DXR for treating MASH, including AKT1, EGFR, TP53, STAT3, and IL6, with biological processes related to oxidative stress. Further investigations show that DXR significantly up-regulates p-AKT1, Nrf2, and HO-1, suggesting that this recipe activates both the PI3K/AKT and Keap1/Nrf2 signaling pathways. It is also found that DXR down-regulates the expression levels of key lipogenic enzymes (such as FASN, SCD1, and ACC1) but upregulates CPT1a in hepatocytes. DXR also exhibits significant antioxidant and anti-inflammatory effects, as demonstrated by a marked reduction in MDA levels and inflammatory cytokines (TNF-α, IL-1β, and IL-6), along with the increased activity levels of both SOD and GSH-Px. Additionally, DXR reduces hepatocyte apoptosis by up-regulating Bcl-2 and down-regulating Bax. Molecular dynamics simulations and luciferase reporter assays show that four flavonoids in DXR are key active constituents to activate the PI3K/AKT and Keap1/Nrf2 signaling pathways. Specifically, quercetin promotes AKT1 phosphorylation, while four flavonoids activate Nrf2 signaling, with apigenin exhibiting the most potent effect. Conclusions: DXR effectively ameliorates MASH in a mouse model by reducing hepatic steatosis, inflammation, and oxidative stress. Its mechanism of action involves the suppression of lipid synthesis and the prevention of hepatocyte apoptosis, achieved by modulating key anti-inflammatory and antioxidant signaling pathways. Flavonoids (such as apigenin and quercetin) are identified as the key active ingredients in DXR responsible for activating Keap1/Nrf2 and PI3K/AKT signaling pathways.
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1772033
Open AccessDaixie recipe ameliorates diet-induced MASH in mice via activating PI3K/AKT and Keap1/Nrf2 signaling
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a highly prevalent liver disease that can progress to cirrhosis and hepatocellular carcinoma. Despite its growing clinical burden, effective therapies remain limited. Daixie recipe (DXR), derived from Danggui Shaoyao San in Jingui Yaolue , has shown notable clinical efficacy in treating MASH, yet its underlying pharmacological mechanisms remain to be clarified. Purpose: To clarify the pharmacological effects of DXR and to elucidate the underlying mechanisms of DXR for treating MASH. Methods: UHPLC-Q-Orbitrap HRMS was used to identify the phytochemcials in DXR. The key targets and ingredients for combating MASH were explored by using a suite of in vitro and in vivo experiments, as well as molecular dynamics simulations and bioinformatics analysis. The MASH model was established in C57BL/6 male mice by feeding either a high-fat, high-fructose, high-cholesterol diet or a methionine- and choline-deficient (MCD) diet. ELISA and Western Blotting were used to measure liver tissue pathology, serum biochemistry, lipid synthesis enzymes, oxidative stress markers, pro-inflammatory mediators, apoptosis-related factors, and p -AKT1, Nrf2, and HO-1 expression. The effects of DXR on the PI3K/AKT pathway and Keap1/Nrf2 signaling were analyzed in free fatty acid-induced AML12 cells and HEK293-Nrf2-Luc cells. Results: DXR shows significant therapeutic efficacy in ameliorating hepatic steatosis and inflammation, as evidenced by the marked reduction in the levels of serum biomarkers (such as ALT, AST, TG, TC, and LDL-c). Phytochemcial analysis coupling with network pharmacology analyses identify key targets of DXR for treating MASH, including AKT1, EGFR, TP53, STAT3, and IL6, with biological processes related to oxidative stress. Further investigations show that DXR significantly up-regulates p-AKT1, Nrf2, and HO-1, suggesting that this recipe activates both the PI3K/AKT and Keap1/Nrf2 signaling pathways. It is also found that DXR down-regulates the expression levels of key lipogenic enzymes (such as FASN, SCD1, and ACC1) but upregulates CPT1a in hepatocytes. DXR also exhibits significant antioxidant and anti-inflammatory effects, as demonstrated by a marked reduction in MDA levels and inflammatory cytokines (TNF-α, IL-1β, and IL-6), along with the increased activity levels of both SOD and GSH-Px. Additionally, DXR reduces hepatocyte apoptosis by up-regulating Bcl-2 and down-regulating Bax. Molecular dynamics simulations and luciferase reporter assays show that four flavonoids in DXR are key active constituents to activate the PI3K/AKT and Keap1/Nrf2 signaling pathways. Specifically, quercetin promotes AKT1 phosphorylation, while four flavonoids activate Nrf2 signaling, with apigenin exhibiting the most potent effect. Conclusions: DXR effectively ameliorates MASH in a mouse model by reducing hepatic steatosis, inflammation, and oxidative stress. Its mechanism of action involves the suppression of lipid synthesis and the prevention of hepatocyte apoptosis, achieved by modulating key anti-inflammatory and antioxidant signaling pathways. Flavonoids (such as apigenin and quercetin) are identified as the key active ingredients in DXR responsible for activating Keap1/Nrf2 and PI3K/AKT signaling pathways.
- Open Access
- 9 March 2026
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 64 (1) , 414-434
Multi-target protective effects of Agrimonia pilosa Ledeb. against metabolic dysfunction-associated steatohepatitis in mice
Agrimonia pilosa Ledeb. (AP), a traditional herbal medicine rich in flavonoids, phenolics, triterpenoids, and glycosides, has been widely used for hepatic injury and metabolic disorders. This study integrated in vivo and in vitro experiments, UHPLC-HRMS profiling, network pharmacology, and molecular simulation to elucidate the bioactive constituents and mechanisms of AP against metabolic dysfunction-associated steatohepatitis (MASH). Therapeutic efficacy was evaluated using a MASH mouse model, AML12 hepatocytes, and RAW264.7 macrophages. Active constituents were identified by UHPLC-HRMS, and potential targets were predicted via SwissTargetPrediction and GEO databases, followed by PPI network construction, GO/KEGG enrichment analysis, molecular docking, and molecular dynamics simulation. AP markedly reduced body weight, liver index, and serum AST, ALT, TG, TC, and LDL-c levels, and attenuated hepatic steatosis, inflammation, and fibrosis. In AML12 cells, AP suppressed lipogenesis by downregulating SREBP-1c, FASN, and SCD1, while promoting fatty acid β-oxidation through CPT1A upregulation. In RAW264.7 macrophages, AP inhibited LPS-induced expression of TNF-α, IL-1β, and IL-6. A total of 83 active constituents and 25 key targets were identified, with HMGCR and AXL emerging as hub nodes. Agrimol B (AGB) exhibited favorable binding affinity and structural stability toward both targets. Mechanistically, AGB inhibited HMGCR, reduced SREBP-2 nuclear translocation, and enhanced LXRα/β-mediated cholesterol efflux, maintaining hepatic cholesterol homeostasis. These findings demonstrate that AP ameliorates MASH through coordinated regulation of lipid metabolism, inflammatory suppression, and collagen deposition, with AGB representing a promising bioactive candidate warranting further investigation.
- 9 March 2026
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 64 (1) , 414-434
Open AccessMulti-target protective effects of Agrimonia pilosa Ledeb. against metabolic dysfunction-associated steatohepatitis in mice
Agrimonia pilosa Ledeb. (AP), a traditional herbal medicine rich in flavonoids, phenolics, triterpenoids, and glycosides, has been widely used for hepatic injury and metabolic disorders. This study integrated in vivo and in vitro experiments, UHPLC-HRMS profiling, network pharmacology, and molecular simulation to elucidate the bioactive constituents and mechanisms of AP against metabolic dysfunction-associated steatohepatitis (MASH). Therapeutic efficacy was evaluated using a MASH mouse model, AML12 hepatocytes, and RAW264.7 macrophages. Active constituents were identified by UHPLC-HRMS, and potential targets were predicted via SwissTargetPrediction and GEO databases, followed by PPI network construction, GO/KEGG enrichment analysis, molecular docking, and molecular dynamics simulation. AP markedly reduced body weight, liver index, and serum AST, ALT, TG, TC, and LDL-c levels, and attenuated hepatic steatosis, inflammation, and fibrosis. In AML12 cells, AP suppressed lipogenesis by downregulating SREBP-1c, FASN, and SCD1, while promoting fatty acid β-oxidation through CPT1A upregulation. In RAW264.7 macrophages, AP inhibited LPS-induced expression of TNF-α, IL-1β, and IL-6. A total of 83 active constituents and 25 key targets were identified, with HMGCR and AXL emerging as hub nodes. Agrimol B (AGB) exhibited favorable binding affinity and structural stability toward both targets. Mechanistically, AGB inhibited HMGCR, reduced SREBP-2 nuclear translocation, and enhanced LXRα/β-mediated cholesterol efflux, maintaining hepatic cholesterol homeostasis. These findings demonstrate that AP ameliorates MASH through coordinated regulation of lipid metabolism, inflammatory suppression, and collagen deposition, with AGB representing a promising bioactive candidate warranting further investigation.
- Open Access
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16
Efficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction–associated fatty liver disease (MAFLD): a Bayesian network meta-analysis
Objective: This study aimed to compare the relative efficacy of dietary supplements and pharmacological agents in improving metabolic and oxidative stress outcomes in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) through a systematic review and Bayesian network meta-analysis. Methods: PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched to identify randomized controlled trials (RCTs) published between 1 January 2014, and 3 March 2024, that evaluated the effects of dietary supplements or pharmacological agents on MAFLD. Results: A total of 106 RCTs involving 7,273 participants were included, involving a variety of nutritional and pharmacological interventions. Pharmacological intervention plus bioactive regulator was the most effective in reducing triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C). Nutrient plus pharmacological intervention was the most efficacious in improving glycated hemoglobin (HbA1c) and insulin levels. Pharmacological intervention plus another pharmacological intervention was most effective in reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Phytochemicals significantly reduced interleukin-6 (IL-6), while bioactive metabolic regulators markedly decreased tumor necrosis factor-α (TNF-α). Herbal extracts demonstrated superior effects in enhancing total antioxidant capacity (TAC) and superoxide dismutase (SOD), while oleoylethanolamide (OEA) improved antioxidant enzyme activity and reduced malondialdehyde (MDA) levels. Further analysis revealed that garlic exerted the strongest effect in improving overall antioxidant capacity, whereas L-carnitine showed the most significant efficacy in suppressing lipid peroxidation. Conclusion: Multicomponent or mechanistically complementary interventions exhibited more stable potential benefits in improving glucose and lipid metabolism. Bioactive metabolic regulators (L-carnitine), endogenous lipid regulators (OEA), and herbal extracts (garlic) all demonstrated strong efficacy in enhancing antioxidant defense and alleviating oxidative damage. Further high-quality RCTs are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42024555065.
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16
Open AccessEfficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction–associated fatty liver disease (MAFLD): a Bayesian network meta-analysis
Objective: This study aimed to compare the relative efficacy of dietary supplements and pharmacological agents in improving metabolic and oxidative stress outcomes in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) through a systematic review and Bayesian network meta-analysis. Methods: PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched to identify randomized controlled trials (RCTs) published between 1 January 2014, and 3 March 2024, that evaluated the effects of dietary supplements or pharmacological agents on MAFLD. Results: A total of 106 RCTs involving 7,273 participants were included, involving a variety of nutritional and pharmacological interventions. Pharmacological intervention plus bioactive regulator was the most effective in reducing triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C). Nutrient plus pharmacological intervention was the most efficacious in improving glycated hemoglobin (HbA1c) and insulin levels. Pharmacological intervention plus another pharmacological intervention was most effective in reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Phytochemicals significantly reduced interleukin-6 (IL-6), while bioactive metabolic regulators markedly decreased tumor necrosis factor-α (TNF-α). Herbal extracts demonstrated superior effects in enhancing total antioxidant capacity (TAC) and superoxide dismutase (SOD), while oleoylethanolamide (OEA) improved antioxidant enzyme activity and reduced malondialdehyde (MDA) levels. Further analysis revealed that garlic exerted the strongest effect in improving overall antioxidant capacity, whereas L-carnitine showed the most significant efficacy in suppressing lipid peroxidation. Conclusion: Multicomponent or mechanistically complementary interventions exhibited more stable potential benefits in improving glucose and lipid metabolism. Bioactive metabolic regulators (L-carnitine), endogenous lipid regulators (OEA), and herbal extracts (garlic) all demonstrated strong efficacy in enhancing antioxidant defense and alleviating oxidative damage. Further high-quality RCTs are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42024555065.
- Open Access
- 26 January 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e80993
Effectiveness and Safety of Kangjia Decoction Granules for the Treatment of Hashimoto Thyroiditis: Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Clinical Trial
Background: Hashimoto thyroiditis (HT) is a chronic inflammation of the thyroid gland mediated by autoimmune disorders, often leading to hypothyroidism and a significant reduction in a patient’s quality of life. At the time of this writing, there is a lack of effective clinical treatments for early-stage HT. Kangjia decoction granules (KDGs) were developed based on clinical experience and results analysis, showing promising outcomes in improving antibody levels and quality of life in patients with HT. However, there is a lack of further evaluation of the efficacy and safety of KDGs. Objective: This pilot study aims to further understand and validate the efficacy and safety of KDGs for treating HT through clinical research and comprehensively assess the benefits of this intervention for patients. Methods: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Participants meeting the HT diagnostic criteria will be randomly allocated to the intervention and control groups (n1=n2=70). The intervention group will receive KDG treatment, whereas the control group will receive a placebo treatment. All participants will undergo treatment for 3 months. Changes in antithyroid peroxidase antibody (TPOAb) levels will be the primary outcome. Secondary outcomes include antithyroglobulin antibodies (TGAb), thyrotropin, also known as thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroid hormone (T4), serum free triiodothyronine (FT3), serum free thyroxine (FT4), thyroid ultrasonography, IL17 mRNA and FOXP3 mRNA, traditional Chinese medicine (TCM) syndrome efficacy scores, and quality of life scale scores. Throughout the treatment and follow-up periods, safety indicators, such as routine blood and urine tests, hepatic and renal function, electrocardiography, and major adverse reactions, will be monitored. Results: The research protocol and informed consent form received approval from the Clinical Research Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with Shanghai University of Traditional Chinese Medicine, on December 14, 2022 (Approval No. 2022-123). Participant recruitment commenced in June 2023. All intervention and concurrent data collection activities were scheduled for completion by October 2025. Data management is still ongoing; therefore, data analysis has not yet been performed. Conclusions: This study’s findings will offer initial clinical evidence regarding the efficacy of the TCM compound KDGs in modulating peripheral immunity in patients with HT, decreasing autoimmune antibody levels, ameliorating TCM syndromes, and enhancing quality of life. These results will serve as a basis for future large-scale trial designs. Trial Registration: China Clinical Trials Registry ChiCTR2300070184; https://www.chictr.org.cn/showprojEN.html?proj=189169 International Registered Report Identifier (IRRID): DERR1-10.2196/80993
- 26 January 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e80993
Open AccessEffectiveness and Safety of Kangjia Decoction Granules for the Treatment of Hashimoto Thyroiditis: Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Clinical Trial
Background: Hashimoto thyroiditis (HT) is a chronic inflammation of the thyroid gland mediated by autoimmune disorders, often leading to hypothyroidism and a significant reduction in a patient’s quality of life. At the time of this writing, there is a lack of effective clinical treatments for early-stage HT. Kangjia decoction granules (KDGs) were developed based on clinical experience and results analysis, showing promising outcomes in improving antibody levels and quality of life in patients with HT. However, there is a lack of further evaluation of the efficacy and safety of KDGs. Objective: This pilot study aims to further understand and validate the efficacy and safety of KDGs for treating HT through clinical research and comprehensively assess the benefits of this intervention for patients. Methods: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Participants meeting the HT diagnostic criteria will be randomly allocated to the intervention and control groups (n1=n2=70). The intervention group will receive KDG treatment, whereas the control group will receive a placebo treatment. All participants will undergo treatment for 3 months. Changes in antithyroid peroxidase antibody (TPOAb) levels will be the primary outcome. Secondary outcomes include antithyroglobulin antibodies (TGAb), thyrotropin, also known as thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroid hormone (T4), serum free triiodothyronine (FT3), serum free thyroxine (FT4), thyroid ultrasonography, IL17 mRNA and FOXP3 mRNA, traditional Chinese medicine (TCM) syndrome efficacy scores, and quality of life scale scores. Throughout the treatment and follow-up periods, safety indicators, such as routine blood and urine tests, hepatic and renal function, electrocardiography, and major adverse reactions, will be monitored. Results: The research protocol and informed consent form received approval from the Clinical Research Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with Shanghai University of Traditional Chinese Medicine, on December 14, 2022 (Approval No. 2022-123). Participant recruitment commenced in June 2023. All intervention and concurrent data collection activities were scheduled for completion by October 2025. Data management is still ongoing; therefore, data analysis has not yet been performed. Conclusions: This study’s findings will offer initial clinical evidence regarding the efficacy of the TCM compound KDGs in modulating peripheral immunity in patients with HT, decreasing autoimmune antibody levels, ameliorating TCM syndromes, and enhancing quality of life. These results will serve as a basis for future large-scale trial designs. Trial Registration: China Clinical Trials Registry ChiCTR2300070184; https://www.chictr.org.cn/showprojEN.html?proj=189169 International Registered Report Identifier (IRRID): DERR1-10.2196/80993
- Open Access
- 1 January 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 7
Association between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017–2020
Original Article Association between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017–2020 Yunyi Yang, Weijin Huang, Xiaoli He, Xiaoxiao Qu, Jiayuan Cai, Fengzhu Zhou, Ningwei Wang, Jiawen You, Xinyi Fu, Yanming He, Zheng Yao, Hongjie Yang
- 1 January 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 7
Open AccessAssociation between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017–2020
Original Article Association between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017–2020 Yunyi Yang, Weijin Huang, Xiaoli He, Xiaoxiao Qu, Jiayuan Cai, Fengzhu Zhou, Ningwei Wang, Jiawen You, Xinyi Fu, Yanming He, Zheng Yao, Hongjie Yang
- Open Access
- 23 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Effectiveness and Safety of Kangjia Decoction Granules for the Treatment of Hashimoto Thyroiditis: Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Clinical Trial (Preprint)
BACKGROUND Hashimoto thyroiditis (HT) is a chronic inflammation of the thyroid gland mediated by autoimmune disorders, often leading to hypothyroidism and a significant reduction in a patient’s quality of life. At the time of this writing, there is a lack of effective clinical treatments for early-stage HT. Kangjia decoction granules (KDGs) were developed based on clinical experience and results analysis, showing promising outcomes in improving antibody levels and quality of life in patients with HT. However, there is a lack of further evaluation of the efficacy and safety of KDGs. OBJECTIVE This pilot study aims to further understand and validate the efficacy and safety of KDGs for treating HT through clinical research and comprehensively assess the benefits of this intervention for patients. METHODS This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Participants meeting the HT diagnostic criteria will be randomly allocated to the intervention and control groups (n1=n2=70). The intervention group will receive KDG treatment, whereas the control group will receive a placebo treatment. All participants will undergo treatment for 3 months. Changes in antithyroid peroxidase antibody (TPOAb) levels will be the primary outcome. Secondary outcomes include antithyroglobulin antibodies (TGAb), thyrotropin, also known as thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroid hormone (T4), serum free triiodothyronine (FT3), serum free thyroxine (FT4), thyroid ultrasonography, IL17 mRNA and FOXP3 mRNA, traditional Chinese medicine (TCM) syndrome efficacy scores, and quality of life scale scores. Throughout the treatment and follow-up periods, safety indicators, such as routine blood and urine tests, hepatic and renal function, electrocardiography, and major adverse reactions, will be monitored. RESULTS The research protocol and informed consent form received approval from the Clinical Research Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with Shanghai University of Traditional Chinese Medicine, on December 14, 2022 (Approval No. 2022-123). Participant recruitment commenced in June 2023. All intervention and concurrent data collection activities were scheduled for completion by October 2025. Data management is still ongoing; therefore, data analysis has not yet been performed. CONCLUSIONS This study’s findings will offer initial clinical evidence regarding the efficacy of the TCM compound KDGs in modulating peripheral immunity in patients with HT, decreasing autoimmune antibody levels, ameliorating TCM syndromes, and enhancing quality of life. These results will serve as a basis for future large-scale trial designs. CLINICALTRIAL China Clinical Trials Registry ChiCTR2300070184; https://www.chictr.org.cn/showprojEN.html?proj=189169 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/80993
- 23 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffectiveness and Safety of Kangjia Decoction Granules for the Treatment of Hashimoto Thyroiditis: Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Clinical Trial (Preprint)
BACKGROUND Hashimoto thyroiditis (HT) is a chronic inflammation of the thyroid gland mediated by autoimmune disorders, often leading to hypothyroidism and a significant reduction in a patient’s quality of life. At the time of this writing, there is a lack of effective clinical treatments for early-stage HT. Kangjia decoction granules (KDGs) were developed based on clinical experience and results analysis, showing promising outcomes in improving antibody levels and quality of life in patients with HT. However, there is a lack of further evaluation of the efficacy and safety of KDGs. OBJECTIVE This pilot study aims to further understand and validate the efficacy and safety of KDGs for treating HT through clinical research and comprehensively assess the benefits of this intervention for patients. METHODS This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Participants meeting the HT diagnostic criteria will be randomly allocated to the intervention and control groups (n1=n2=70). The intervention group will receive KDG treatment, whereas the control group will receive a placebo treatment. All participants will undergo treatment for 3 months. Changes in antithyroid peroxidase antibody (TPOAb) levels will be the primary outcome. Secondary outcomes include antithyroglobulin antibodies (TGAb), thyrotropin, also known as thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroid hormone (T4), serum free triiodothyronine (FT3), serum free thyroxine (FT4), thyroid ultrasonography, IL17 mRNA and FOXP3 mRNA, traditional Chinese medicine (TCM) syndrome efficacy scores, and quality of life scale scores. Throughout the treatment and follow-up periods, safety indicators, such as routine blood and urine tests, hepatic and renal function, electrocardiography, and major adverse reactions, will be monitored. RESULTS The research protocol and informed consent form received approval from the Clinical Research Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with Shanghai University of Traditional Chinese Medicine, on December 14, 2022 (Approval No. 2022-123). Participant recruitment commenced in June 2023. All intervention and concurrent data collection activities were scheduled for completion by October 2025. Data management is still ongoing; therefore, data analysis has not yet been performed. CONCLUSIONS This study’s findings will offer initial clinical evidence regarding the efficacy of the TCM compound KDGs in modulating peripheral immunity in patients with HT, decreasing autoimmune antibody levels, ameliorating TCM syndromes, and enhancing quality of life. These results will serve as a basis for future large-scale trial designs. CLINICALTRIAL China Clinical Trials Registry ChiCTR2300070184; https://www.chictr.org.cn/showprojEN.html?proj=189169 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/80993
- Open Access
- 20 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5677-5679
Letter to the Editor: comment on “Intra- and early postoperative predictors of delirium risk in cardiac surgery: results from the prospective observational FINDERI study”
An abstract is unavailable. This article is available as a PDF only.
- 20 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5677-5679
Open AccessLetter to the Editor: comment on “Intra- and early postoperative predictors of delirium risk in cardiac surgery: results from the prospective observational FINDERI study”
An abstract is unavailable. This article is available as a PDF only.